Worth Venture Partners’s NLS Pharmaceutics Warrant NLSPW Stock Holding History

Worth Venture Partners’s Portfolio NLSPW Stock Details NLSPW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-194,060	Closed	-$49K	–	194
2022 Q3	$49K	Hold	194,060	–	–	0.03%	143
2022 Q2	$38K	Sell	194,060 -500	-0.3%	-$121	0.02%	130
2022 Q1	$74K	Hold	194,560	–	–	0.03%	124
2021 Q4	$97K	Hold	194,560	–	–	0.05%	111
2021 Q3	$161K	Hold	194,560	–	–	0.07%	108
2021 Q2	$176K	Hold	194,560	–	–	0.07%	103
2021 Q1	$185K	Buy	+194,560	New	+$177K	0.09%	96

Other funds holding NLSPW

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Worth Venture Partners's NLSPW Position: Q4 2022 in Review

Worth Venture Partners sold out of NLS Pharmaceutics Warrant (NLSPW) in Q4 2022, closing a stake of 194,060 shares — an estimated $49K sold.

Worth Venture Partners first reported a position in NLSPW in Q1 2021 and held it in 7 quarters. The position peaked at $185K in Q1 2021. 5 funds tracked by Wall St. Rank hold NLSPW as of Q4 2022.

Worth Venture Partners reported no remaining NLS Pharmaceutics Warrant position as of Q4 2022 after selling out during the quarter.
Worth Venture Partners sold 194,060 NLS Pharmaceutics Warrant shares in Q4 2022, an estimated $49K.
Worth Venture Partners first reported a position in NLS Pharmaceutics Warrant in Q1 2021 and held it in 7 quarters.
Worth Venture Partners's NLS Pharmaceutics Warrant position peaked at $185K in Q1 2021.
5 funds tracked by Wall St. Rank held NLS Pharmaceutics Warrant as of Q4 2022.

Based on Worth Venture Partners's 13F filing for Q4 2022, filed 14 Feb 2023.